Table 1.
Demographic and clinical characteristics at baseline* for patients treated in period II (Withdrawal phase)
| SC abatacept (n=40) | SC placebo (n=80) | |
|---|---|---|
| Age (years) | 48.9 (14.2) | 49.1 (12.8) |
| Weight (kg) | 67.9 (15.8) | 68.9 (14.7) |
| Weight category, n (%) | ||
| <60 kg | 14 (35.0) | 19 (23.8) |
| 60–100 kg | 25 (62.5) | 60 (75.0) |
| >100 kg | 1 (2.5) | 1 (1.3) |
| Gender (% female) | 85.0 | 83.8 |
| Race (% Caucasian) | 95.0 | 93.8 |
| Disease duration (years) | 7.4 (7.7) | 6.2 (5.8) |
| Tender joints | 13.6 (7.7) | 14.6 (9.2) |
| Swollen joints | 10.5 (5.4) | 10.6 (5.4) |
| Disease activity, DAS28 (CRP) | 4.8 (0.8) | 4.8 (0.8) |
| HAQ-DI | 1.4 (0.7) | 1.3 (0.7) |
| RF positive (%) | 85.0 | 86.1 |
| CRP level (mg/dl) | 1.27 (1.76) | 1.23 (1.54) |
| Prior antirheumatic drug, n (%) | ||
| Systemic corticosteroids | 24 (60) | 41 (51.3) |
| Methotrexate | 40 (100) | 80 (100) |
| Cyclophosphamide | 0 (0) | 1 (1.3) |
| Leflunomide | 0 (0) | 2 (2.5) |
| Etanercept | 1 (2.5) | 2 (2.5) |
| Infliximab | 0 (0) | 4 (5.0) |
| Adalimumab | 2 (5.0) | 2 (2.5) |
Data are mean (SD) unless otherwise stated.
*
Baseline is the start of period I.
CRP, C reactive protein; DAS28, Disease Activity Score 28; HAQ-DI, Health Assessment Questionnaire-Disability Index; RF, rheumatoid factor; SC, subcutaneous.